Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "engineers"

65 News Found

Siemens Healthineers launches €10 million R&D hub in Swords, Ireland
R&D | February 04, 2026

Siemens Healthineers launches €10 million R&D hub in Swords, Ireland

The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders


Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
News | January 31, 2026

Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub

The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians


Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Opinion | January 07, 2026

Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader

India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry


Lilly to invest $6 billion in Huntsville manufacturing hub
News | December 10, 2025

Lilly to invest $6 billion in Huntsville manufacturing hub

The new site will produce next-generation synthetic medicine active pharmaceutical ingredients


Effective corrosion management demands a holistic approach: Experts
News | November 04, 2025

Effective corrosion management demands a holistic approach: Experts

From material selection to cooling tower management, every small decision affects long-term equipment reliability


Lilly to build $3 billion oral medicine facility in Netherlands
News | November 04, 2025

Lilly to build $3 billion oral medicine facility in Netherlands

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain


Industry leaders call for a new era of collaboration, innovation, and self-reliance
News | November 03, 2025

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases